公司资料
bioAffinity Technologies, Inc. 股价、新闻与催化剂
- 股票代码:
- BIAF
- 交易所:
- NASDAQ
- 行业:
- MedTech
- 所在地:
- United States
股票表现
0.39 USD (-2.51%)
收盘价
最后更新: 2026年8月17日
7.62M USD
市值
股价为何变动
The latest monitored company update is “bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung.” The corresponding closing-price reaction is not yet available.
公司概览
Noninvasive Lung Diagnostics
bioAffinity Technologies develops noninvasive tests for the early detection and characterization of lung disease. Its approach uses flow-cytometry and artificial-intelligence analysis of cells collected from sputum samples.
CyPath Lung
CyPath Lung is a laboratory-developed test intended to help assess patients at elevated risk of lung cancer, including those with indeterminate imaging findings. It is positioned between imaging surveillance and invasive diagnostic procedures. The company is also exploring applications of its cellular-analysis platform in asthma and chronic obstructive pulmonary disease, including potential companion-diagnostic uses.
未来催化剂
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。